Rosiglitazone inhibits cell proliferation by inducing G1 cell cycle arrest and apoptosis in ADPKD cyst-lining epithelia cells.

Abnormal proliferation is an important pathological feature of autosomal dominant polycystic kidney disease (ADPKD). Many drugs inhibiting cell proliferation have been proved to be effective in slowing the disease progression in ADPKD. Recent evidence has suggested that peroxisome proliferator-activated receptor gamma (PPARgamma) ligands have anti-neoplasm effects through inhibiting cell growth and inducing cell apoptosis in various cancer cells. In the present study, we examined the expression of PPARgamma in human ADPKD kidney tissues and cyst-lining epithelial cell line, and found that the expression of PPARgamma was greater in ADPKD kidney tissues and cyst-lining epithelial cell line than in normal kidney tissues and human kidney cortex (HKC) cell line. Rosiglitazone inhibited significantly proliferation of cyst-lining epithelial cells in a concentration- and time-dependent manner. These effects were diminished by GW9662, a specific PPARgamma antagonist. Cell cycle analysis showed a G0/G1 arrest in human ADPKD cyst-lining epithelial cells with rosiglitazone treatment. Analysis of cell cycle regulatory proteins revealed that rosiglitazone decreased the protein levels of proliferating cell nuclear antigen, pRb, cyclin D1, cyclin D2 and Cdk4 but increased the levels of p21 and p27 in a dose-dependent manner. Rosiglitazone also induced apoptosis in cyst-lining epithelial cells, which was correlated with increased bax expression and decreased bcl-2 expression. These results suggest PPARgamma agonist might serve as a promising drug for the treatment of ADPKD.

[1]  Takao Masaki,et al.  PPAR-γ agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-β , 2009, Laboratory Investigation.

[2]  R. Pang,et al.  Rosiglitazone Suppresses the Growth and Invasiveness of SGC-7901 Gastric Cancer Cells and Angiogenesis In Vitro via PPARγ Dependent and Independent Mechanisms , 2008, PPAR research.

[3]  Jong-Suk Kim,et al.  Induction of G1 phase arrest and apoptosis in MDA‐MB‐231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator‐activated receptor γ (PPARγ) ligand , 2008, Cell biology international.

[4]  E. Avner,et al.  Src inhibition ameliorates polycystic kidney disease. , 2008, Journal of the American Society of Nephrology : JASN.

[5]  M. Adachi,et al.  Decreased peroxisome proliferator-activated receptor alpha gene expression is associated with dyslipidemia in a rat model of chronic renal failure. , 2007, Metabolism: clinical and experimental.

[6]  Laurie A. Smith,et al.  Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine , 2006, Nature.

[7]  Meguid El Nahas,et al.  Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  Hisahide Takahashi,et al.  Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. , 2006, Journal of the American Society of Nephrology : JASN.

[9]  Xuefei Shen,et al.  Aberrant expression of SPARC and its impact on proliferation and apoptosis in ADPKD cyst-lining epithelia. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  W. Sheu,et al.  Rosiglitazone inhibits endothelial proliferation and angiogenesis. , 2006, Life sciences.

[11]  U. Schumacher,et al.  Ligands for the peroxisome proliferator-activated receptor-gamma have inhibitory effects on growth of human neuroblastoma cells in vitro. , 2005, Toxicology.

[12]  M. Serio,et al.  Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. , 2005, The Journal of clinical endocrinology and metabolism.

[13]  Y. Tao,et al.  Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. , 2004, Journal of the American Society of Nephrology : JASN.

[14]  C. Grommes,et al.  Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists , 2004 .

[15]  P. Duerksen-Hughes,et al.  The Human Papillomavirus 16 E6 Protein Binds to Fas-associated Death Domain and Protects Cells from Fas-triggered Apoptosis* , 2004, Journal of Biological Chemistry.

[16]  Li‐jun Wu,et al.  Oridonin induces apoptosis of HeLa cells via altering expression of Bcl-2/Bax and activating caspase-3/ICAD pathway. , 2004, Acta pharmacologica Sinica.

[17]  E. Avner,et al.  EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats. , 2003, Kidney international.

[18]  Vincent H Gattone,et al.  Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist , 2003, Nature Medicine.

[19]  M. Sutters,et al.  Autosomal dominant polycystic kidney disease: molecular genetics and pathophysiology. , 2003, The Journal of laboratory and clinical medicine.

[20]  Kenji Nakamura,et al.  Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. , 2002, Human molecular genetics.

[21]  Y. Kawahito,et al.  Expression of Peroxisome Proliferator-Activated Receptor γ in Renal Cell Carcinoma and Growth Inhibition by Its Agonists , 2001 .

[22]  M. Breyer,et al.  Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. , 2001, Kidney international.

[23]  B. Spiegelman.  PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.

[24]  J. Bartek,et al.  The retinoblastoma protein pathway in cell cycle control and cancer. , 1997, Experimental cell research.

[25]  J. Auwerx,et al.  Peroxisome proliferator-activated receptors, orphans with ligands and functions. , 1997, Current opinion in lipidology.

[26]  V. D’Agati,et al.  Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD). , 1996, Oncogene.

[27]  J. Grantham,et al.  Polycystic kidney disease: etiology, pathogenesis, and treatment. , 1995, Disease-a-month : DM.

[28]  X. Graña,et al.  Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). , 1995, Oncogene.

[29]  Eric F. Johnson,et al.  Novel Sequence Determinants in Peroxisome Proliferator Signaling (*) , 1995, The Journal of Biological Chemistry.

[30]  James M. Roberts,et al.  Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.

[31]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[32]  M. Lazar,et al.  Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. , 1994, Endocrinology.

[33]  A. Woolf,et al.  Taxol inhibits progression of congenital polycystic kidney disease , 1994, Nature.

[34]  Yves Pirson,et al.  Autosomal dominant polycystic kidney disease , 1992, The Lancet.

[35]  J. Lehmann,et al.  The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways. , 1999, Recent progress in hormone research.

[36]  K. Blick,et al.  Proliferative activity of cyst epithelium in human renal cystic diseases. , 1995, Journal of the American Society of Nephrology.

[37]  E. Lees.  Cyclin dependent kinase regulation. , 1995, Current opinion in cell biology.